Expression of a bee venom phospholipase A2 from Apis cerana cerana in the baculovirus-insect cell

Shen, Lirong; Ding, Meihui; Zhang, Liwen; Zhang, Weiguang; Liu, Liang; Li, Duo

doi:10.1631/jzus.b0900254

Cited by 9 publications

(9 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, many studies have reported the therapeutic effects of melittin against cancers, neurodegenerative diseases and chronic inflammatory diseases including rheumatism (Park et al, 2004; Yang et al, 2011; Rady et al, 2017). It has been suggested that the biological activity of bvPLA 2 can be enhanced by melittin (Mingarro et al, 1995; Shen et al, 2010). Certainly, more detailed sets of experimental investigations are needed to verify its potential usefulness in the future applications.…”

Section: Discussionmentioning

confidence: 99%

Dose-Dependent Neuroprotective Effect of Standardized Bee Venom Phospholipase A2 Against MPTP-Induced Parkinson’s Disease in Mice

Kim

Lee

Shin

et al. 2019

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a chronic progressive neurodegenerative movement disorder characterized by the selective loss of dopaminergic neurons within the substantia nigra (SN). While the precise etiology of dopaminergic neuronal demise is elusive, multiple lines of evidence indicate that neuroinflammation is involved in the pathogenesis of PD. We have previously demonstrated that subcutaneous administration of bee venom (BV) phospholipase A 2 (bvPLA 2 ) suppresses dopaminergic neuronal cell death in a PD mouse model. In the present study, we established standardized methods for producing bvPLA 2 agent isolated from crude BV at good manufacturing practice (GMP) facility. The therapeutic efficacy of purified bvPLA2 agent was examined in MPTP-induced PD mice. Importantly, administration of purified bvPLA 2 in a dose-dependent manner reversed motor deficits in PD mice as well as inhibited loss of dopaminergic neurons within the SN of PD mice. The concentration-dependent action of standardized bvPLA 2 appeared to be related to the induction of CD4 + CD25 + Foxp3 + regulatory T cells (Tregs), which, in part, inhibits T helper 1 (Th1) and Th17 polarization and suppresses microglial activation in PD mice. Taken together, these results suggest that standardized bvPLA 2 purified from BV shows a neuroprotective effect against PD and thus has a potential target for treatment of PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Dose-Dependent Neuroprotective Effect of Standardized Bee Venom Phospholipase A2 Against MPTP-Induced Parkinson’s Disease in Mice

Kim

Lee

Shin

et al. 2019

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…The primary sequence contains eight cysteine residues involved in the formation of four disulfide bonds and one N-glycosylated residue (Asn13) (Hoffman, 2006;Shipolini et al, 1974). Unlike snake PLA2 from elapid (Class IA) and viper (Class IIA/IIB) venoms, Api m 1 belongs to Group III of bee/lizard/scorpion, secretory and Ca 2þ -dependent venom PLA2s (Hoffman, 2006;Shen et al, 2010). The enzyme hydrolyzes the sn-2 ester linkage of glycerophospholipids releasing free fatty acids and lysophospholipids (Dennis et al, 2011), as illustrated in Fig.…”

Section: Phospholipase A2mentioning

confidence: 99%

Diversity of peptidic and proteinaceous toxins from social Hymenoptera venoms

Santos-Pinto

Pérez-Riverol

Lasa

et al. 2018

Toxicon

View full text Add to dashboard Cite

Among venomous animals, Hymenoptera have been suggested as a rich source of natural toxins. Due to their broad ecological diversity, venom from Hymenoptera insects (bees, wasps and ants) have evolved differentially thus widening the types and biological functions of their components. To date, insect toxinology analysis have scarcely uncovered the complex composition of bee, wasp and ant venoms which include low molecular weight compounds, highly abundant peptides and proteins, including several allergens. In Hymenoptera, these complex mixtures of toxins represent a potent arsenal of biological weapons that are used for self-defense, to repel intruders and to capture prey. Consequently, Hymenoptera venom components have a broad range of pharmacological targets and have been extensively studied, as promising sources of new drugs and biopesticides. In addition, the identification and molecular characterization of Hymenoptera venom allergens have allowed for the rational design of component-resolved diagnosis of allergy, finally improving the outcome of venom immunotherapy (VIT). Until recently, a limited number of Hymenoptera venoms had been unveiled due to the technical limitations of the approaches used to date. Nevertheless, the application of novel techniques with high dynamic range has significantly increased the number of identified peptidic and proteinaceous toxins. Considering this, the present review summarizes the current knowledge about the most representative Hymenoptera venom peptides and proteins which are under study for a better understanding of the insect-caused envenoming process and the development of new drugs and biopesticides.

show abstract

“…87% and greatly impaired parasite transmission to naive mice (Moreira et al, 2002). There is great industrial and pharmaceutical interest in phospholipases due to their association with many human disorders so that the recent production of recombinant bee PLA 2 in an insect cell line is significant (Shen et al, 2010). Similarly, hyaluronidases have many uses in medicine including helping the spread of drugs in tissues and as anti-cancer agents, so that the production of a recombinant honey bee hyaluronidase may provide a new drug with great commercial potential (Reitinger et al, 2008).…”

Section: Phospholipases and Hyaluronidasementioning

confidence: 99%